Certara, Inc. (NASDAQ:CERT) Receives Consensus Recommendation of “Hold” from Brokerages

Certara, Inc. (NASDAQ:CERT) has received an average rating of “Hold” from the eight ratings firms that are currently covering the company, MarketBeat Ratings reports. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $15.92.

CERT has been the topic of a number of recent analyst reports. Barclays cut their price objective on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday, November 7th. Robert W. Baird cut their price objective on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 5th. Finally, UBS Group upgraded shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective on the stock in a research note on Friday, September 27th.

Insiders Place Their Bets

In related news, insider Patrick F. Smith sold 5,409 shares of Certara stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the transaction, the insider now owns 50,091 shares of the company’s stock, valued at approximately $552,503.73. This trade represents a 9.75 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.39% of the stock is owned by company insiders.

Hedge Funds Weigh In On Certara

Institutional investors have recently bought and sold shares of the stock. Blue Trust Inc. grew its stake in Certara by 112.3% during the 3rd quarter. Blue Trust Inc. now owns 3,925 shares of the company’s stock valued at $46,000 after acquiring an additional 2,076 shares in the last quarter. KBC Group NV grew its stake in Certara by 48.2% during the 3rd quarter. KBC Group NV now owns 4,873 shares of the company’s stock valued at $57,000 after acquiring an additional 1,584 shares in the last quarter. Intech Investment Management LLC purchased a new position in Certara during the 2nd quarter valued at about $152,000. Algert Global LLC purchased a new position in Certara during the 2nd quarter valued at about $156,000. Finally, MQS Management LLC purchased a new position in Certara during the 2nd quarter valued at about $162,000. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Stock Performance

CERT stock opened at $10.54 on Tuesday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The stock has a market capitalization of $1.70 billion, a price-to-earnings ratio of -52.70, a PEG ratio of 5.86 and a beta of 1.53. Certara has a 1 year low of $9.41 and a 1 year high of $19.87. The stock’s fifty day moving average is $10.75 and its two-hundred day moving average is $12.20.

Certara (NASDAQ:CERT) last posted its earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. The company had revenue of $94.80 million for the quarter, compared to analysts’ expectations of $95.51 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The firm’s quarterly revenue was up 10.7% compared to the same quarter last year. During the same period last year, the business posted $0.06 earnings per share. On average, research analysts predict that Certara will post 0.28 EPS for the current year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.